Ketamine Addiction Treatment: An Emerging Pathway for Alcoholism and Substance Use

What Is Ketamine Addiction Treatment?

Ketamine addiction treatment refers to the use of low, sub-anesthetic doses of ketamine, delivered in a supervised clinical setting, alongside a structured course of psychotherapy aimed at changing drinking or drug-use behavior. It is not a detox protocol, and it is not something ketamine does on its own. In every trial that has produced meaningful results, the medicine was one half of a package, and the therapy was the other half.

This distinction matters more here than in almost any other area of psychedelic medicine. When ketamine is used for depression, the infusion itself carries much of the therapeutic weight. Addiction works differently. The compulsion is embedded in habit, environment, memory, and social context, and none of those change because a receptor was blocked for forty minutes. What the research suggests is that ketamine may open a temporary window in which the brain is more willing to learn something new, and that the value of the window depends entirely on what is put into it.

The mechanism most often proposed is neuroplasticity. Ketamine blocks NMDA glutamate receptors, and the brain responds with a short burst of new synaptic growth, particularly in the prefrontal cortex. In plain terms, the part of the brain responsible for planning, self-control, and stepping back from an impulse becomes briefly more flexible. Researchers describe this as a critical window that lasts roughly a few days. Therapy delivered inside that window may take hold more firmly than the same therapy delivered a month later.

There is a second proposed mechanism worth knowing about, and it is less discussed. Addictive behavior is partly maintained by memory. The sight of a bar, the end of a hard workweek, the specific ritual of pouring a drink. Some researchers think ketamine may interfere with the reconsolidation of those cue-based memories, weakening the automatic link between trigger and craving. That idea remains speculative. It is a hypothesis with early support, not a demonstrated fact.

What Does the Research on Ketamine and Alcoholism Show?

The most rigorous work to date is the KARE trial, run out of the University of Exeter and University College London and published in the American Journal of Psychiatry in 2022. Ninety-six adults with alcohol use disorder, all abstinent at the start, were randomly assigned to receive either three ketamine infusions or a saline placebo, and either mindfulness-based relapse prevention therapy or an alcohol education control. That two-by-two design is what makes the trial useful, because it lets researchers separate the drug effect from the therapy effect rather than lumping them together.

The finding that gets quoted most often is the abstinence figure at six months. Participants who received ketamine plus relapse-prevention therapy stayed abstinent on roughly 86 percent of days, compared with about 76 percent in the comparison group. That is a real difference and it held for half a year, which is longer than most addiction interventions can claim. The infusions were well tolerated, with no serious adverse events attributed to the drug.

Here is where honest framing is required. Ninety-six participants is a small sample for a condition as common and as heterogeneous as alcohol use disorder. Everyone in the trial was already abstinent when they enrolled, which means the study tested relapse prevention, not getting sober in the first place. Those are different clinical problems. And the trial was not powered to prove that ketamine alone would have done anything without the therapy attached. The signal is genuine. The conclusion is not yet available.

A separate pilot trial from Columbia University, published in 2020, took a different angle. Forty adults with alcohol use disorder who were still drinking received a single ketamine infusion or a midazolam control, paired with motivational enhancement therapy. The ketamine group showed a greater reduction in heavy drinking, but with forty participants this is a signal to investigate, not a result to build a treatment plan around.

What About Ketamine for Cocaine and Other Substances?

The cocaine research comes from the same Columbia group, led by Elias Dakwar, and the headline number is striking enough that it deserves careful handling. Fifty-five people with cocaine dependence received either a single ketamine infusion or midazolam, both alongside a five-week course of mindfulness-based relapse prevention. In the final two weeks of the trial, about 48 percent of the ketamine group had maintained abstinence, compared with roughly 11 percent of the control group.

That is a large gap. It is also a gap generated by fifty-five people in a single trial at a single site, and cocaine use disorder currently has no approved pharmacological treatment at all, which means the bar for excitement is low and the temptation to overstate is high. The result has not been replicated at scale. Until it is, the correct posture is interest rather than confidence.

For opioids, the evidence is thinner still. There are case reports, small open-label studies, and a plausible theoretical rationale, but nothing approaching a well-powered randomized trial. Ketamine is sometimes discussed as an adjunct for the depression and anhedonia that accompany opioid recovery rather than as a treatment for opioid dependence itself, and that framing is more defensible than the alternative. For opioid use disorder specifically, buprenorphine and methadone remain the treatments with decades of survival data behind them. Nothing in the ketamine literature justifies stepping away from them.

Where Does This Sit on the Evidence Scale?

We treat ketamine addiction treatment as early-stage evidence, and we say so plainly because the alternative is a form of dishonesty that costs people money and time. Compare it against ketamine for treatment-resistant depression, where dozens of trials, thousands of participants, and an approved derivative (esketamine) support the use case. Addiction has nothing like that. It has a handful of small trials, mostly in alcohol and cocaine, mostly conducted by two research groups, mostly unreplicated.

There is also a fact that anyone considering this path should sit with. Ketamine itself carries abuse potential. It has a real history of recreational misuse, and chronic heavy use is associated with bladder damage and cognitive problems. Giving a drug with abuse liability to a person whose defining vulnerability is abuse liability is not a trivial decision. In the clinical trials this risk was managed with supervised administration, controlled dosing, and no take-home supply. In some commercial at-home ketamine programs, none of those safeguards exist. That gap is the single most important practical thing in this article.

The distinction between clinic-supervised and at-home models is covered in more depth in our guide to preparing for ketamine therapy, and it is worth reading before you choose a provider.

What Would a Responsible Ketamine Program for Addiction Look Like?

If someone is going to pursue this, the structure of the program matters more than the molecule. The trials that worked shared a set of features, and any credible provider should be able to demonstrate all of them.

• Supervised, in-person administration. No take-home doses, no unmonitored self-dosing, no exceptions for people with a substance use history.
• Psychotherapy built into the protocol, not offered as an upsell. Mindfulness-based relapse prevention and motivational enhancement therapy are the two approaches with actual trial support behind them.
• Sessions scheduled inside the plasticity window. Therapy delivered in the days immediately after an infusion, when the research suggests the brain is most receptive.
• Medical screening that takes cardiac and psychiatric history seriously. Ketamine raises blood pressure, and a history of psychosis is a meaningful concern.
• A stated position on what happens if it does not work. A provider who has no answer to that question is selling something rather than treating something.

Notice that four of those five items have nothing to do with ketamine. That is the point. The infusion is the smallest part of a well-run program, and any clinic that presents it as the whole intervention has misread its own evidence base.

Should You Consider Ketamine for Addiction?

Ketamine is not a first-line treatment for any addiction, and it should not displace approaches with stronger evidence. For alcohol use disorder, naltrexone and acamprosate have far more data behind them. For opioid use disorder, medication-assisted treatment is the standard of care and has been for good reason. Behavioral therapies and recovery communities remain foundational regardless of what medicine is involved.

Where ketamine may reasonably enter the conversation is for people who have engaged seriously with those options and found them insufficient, who are working with a clinical team rather than around one, and who understand that they would be accepting an early-evidence intervention with a known abuse profile. That is a narrower group than the marketing around this field would suggest, and it is a conversation to have with a physician who knows your full history, not with a clinic sales page.

If depression is tangled up with the drinking or drug use, and it very often is, the evidence for ketamine addressing that side of the picture is considerably stronger. Our comparison of psilocybin and ketamine therapy covers what that research actually supports. The psilocybin research on alcohol use disorder is worth understanding as well, since the mechanisms and the trial designs differ meaningfully.

What we can say with confidence is this. There is a genuine research signal here, it is being taken seriously by serious people, and it is nowhere near strong enough to justify the certainty with which some providers market it. Anyone who tells you otherwise is ahead of the data.